Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966194 | 0.91 | CALCA (0.42) | CALCATP53ADORA2AL3MBTL1THRB | |
| SCHEMBL969545 | 0.90 | CALCA (0.41) | CALCATP53ADORA2AL3MBTL1THRB | |
| SCHEMBL968739 | 0.89 | CALCA (0.41) | CALCATP53ADORA2AL3MBTL1THRB | |
| SCHEMBL967580 | 0.89 | ADORA2A (0.42) | CALCATP53ADORA2AL3MBTL1THRB | |
| SCHEMBL968296 | 0.89 | CALCA (0.41) | CALCATP53ADORA2AL3MBTL1THRB | |
| SCHEMBL967711 | 0.88 | APLNR (0.40) | CALCATP53ADORA2AL3MBTL1THRB | |
| SCHEMBL969973 | 0.87 | NPSR1 (0.42) | CALCATP53ADORA2AL3MBTL1THRB | |
| SCHEMBL3964597 | 0.87 | EGLN1 (0.46) | CALCATP53L3MBTL1THRBMAPT | |
| SCHEMBL965385 | 0.85 | CALCA (0.39) | CALCATP53L3MBTL1THRBMAPT | |
| SCHEMBL966267 | 0.84 | TP53 (0.42) | CALCATP53L3MBTL1THRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | claimed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | PCNA, SAMHD1, NTPCR | CALCA 4461/4885TP53 1946/4885ADORA2A 3883/4885 |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | PCNA, SAMHD1, NTPCR | CALCA 4461/4885TP53 1946/4885ADORA2A 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.